Pulse steroid therapy in infantile facial hemangiomas: the early experience

Pardeep Bhatia, Preet Mohan Singh, Vaibhav Sharma, Manu Kohli


Background: To investigate the efficacy and safety of Pulse steroid therapy in the management of Infantile facial hemangioma in five subjects.

Methods: Consecutive patients who presented with facial hemangioma were prospectively enrolled in this study between January 2014 till August 2017. All subjects underwent treatment with 30mg/kg/day I/V methyl prednisolone for 6days and then weekly for 6weeks and then followed by oral daily dosing. All subjects underwent systemic, and radiologic evaluations before treatment and at periodic intervals after starting therapy. Side effects from therapy were also evaluated.

Results: Five subjects under 6 months of age, with facial hemangioma were enrolled in this study. After hospital admission, I/V steroid therapy was initiated in all subjects under monitoring by a pediatric cardiologist. Subsequent oral therapy after 6 weeks was performed with periodic out-patient monitoring. All subjects had excellent response to treatment, with regression of facial hemangioma. There were no side effects from therapy.

Conclusions: I/V methyl prednisolone pulse steroid therapy for facial hemangioma was effective in all the five subjects.



Infantile facial hemangioma, Pulse steroid therapy

Full Text:



Bivings L. Spontaneous regression of angiomas in children: twenty-two years’ observation covering 236 cases. J Pediatr. 1954;45(6):643-7.

Bowers RE, Graham EA, Tominson KM. The natural history of the strawberry nevus. Arch Dermatol. 1960;82(5):667-70.

Jacobs AH. Strawberry hemangiomas: the natural history of the untreated lesion. Calif Med. 1957;86(1):8-10.

Tollefson MM, Frieden IJ. Early growth of infantile hemangiomas: what parents' photographs tell us. Pediatrics. 2012;130(2):e314-20.

Chang LC, Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, et al. Hemangioma Investigator Group. Growth characteristics of infantile hemangiomas: implications for management. Pediat. 2008;122(2):360-7.

Bhattacharya JJ, Luo CB, Alvarez H, Rodesch G, Pongpech S, Lasjaunias PL. PHACES syndrome: A review of eight previously unreported cases with late arterial occlusions. Neuroradiol. 2004;46:227-33.

Burrows PE, Robertson RL, Mulliken JB, Beardsley DS, Chaloupka JC, Ezekowitz RA, et al. Cerebral vasculopathy and neurologic sequelae in infants with cervicofacial hemangioma: Report of eight patients. Radiol. 1998;207:601-7.

Drolet BA, Dohil M, Golomb MR, Wells R, Murowski L, Tamburro J, et al. Early stroke and cerebral vasculopathy in children with facial hemangiomas and PHACE association. Pediatr. 2006;117:959-64.

Drolet BA, Chamlin SL, Garzon MC, Adams D, Baselga E, Haggstrom AN, et al. Prospective study of spinal anomalies in children with infantile hemangiomas of the lumbosacral skin. J Pediatr. 2010;157:789-94.

Dickie B, Dasgupta R, Nair R, Alonso MH, Ryckman FC, Tiao GM, et al. Spectrum of hepatic hemangiomas: Management and outcome. J Pediatr Surg. 2009;44:125-33.

Kulungowski AM, Alomari AI, Chawla A, Christison-Lagay ER, Fishman SJ. Lessons from a liver hemangioma registry: Subtype classification. J Pediatr Surg. 2012;47:165-70.

Frieden IJ, Eichenfield LF, Esterly NB, Geronemus R, Mallory SB. Guidelines of care for hemangiomas of infancy. J Am Acad Dermatol.1997;37:631-7.

Khan ZA, Boscolo E, Picard A, Psutka S, Melero-Martin JM, Bartch TC, et al. Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. J Clin Invest. 2008;118:2592-9.

Greenberger S, Boscolo E, Adini I, Mulliken JB, Bischoff J. Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells. N Engl J Med. 2010;362:1005-13.

Uysal KM, Olgun N, Erbay A, Sarialioglu F. High-dose oralmethylprednisolone therapy in childhood hemangiomas. Pediatr Hematol Oncol. 2001;18:335-41.